We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
+6.68%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.16B
AUM Growth
+$596M
Cap. Flow
+$655M
Cap. Flow %
30.37%
Top 10 Hldgs %
48.34%
Holding
102
New
45
Increased
15
Reduced
8
Closed
34

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$93.9M
2
BIIB icon
Biogen
BIIB
+$87.9M
3
AKBA icon
Akebia Therapeutics
AKBA
+$64.3M
4
AVTR icon
Avantor
AVTR
+$61.3M
5
TMO icon
Thermo Fisher Scientific
TMO
+$48.9M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$82.4M
2
IMMU
Immunomedics Inc
IMMU
+$67.7M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$57M
4
HOLX
Hologic
HOLX
+$46.6M
5
EXEL icon
Exelixis
EXEL
+$44.9M

Sector Composition

Rank Sector Weight
1 Healthcare 80.12%
2 Technology 1.7%
3 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACIU icon
51
AC Immune
ACIU
$231M
$7.56M 0.35%
+1,550,000
New +$11.1M
ALPN
52
DELISTED
Alpine Immune Sciences Inc
ALPN
$7.12M 0.33%
+810,000
New +$7.41M
VSPRU
53
DELISTED
Vesper Healthcare Acquisition Corp. Unit
VSPRU
$6.16M 0.29%
+600,000
New +$6.16M
CLVS
54
DELISTED
Clovis Oncology, Inc.
CLVS
$5.83M 0.27%
+1,000,000
New +$5.98M
ARYBU
55
DELISTED
ARYA Sciences Acquisition Corp II Unit
ARYBU
$5.41M 0.25%
+500,000
New +$5.67M
OSH
56
DELISTED
Oak Street Health, Inc.
OSH
$5.34M 0.25%
+100,000
New +$4.48M
PMVP icon
57
PMV Pharmaceuticals
PMVP
$57.1M
$5.33M 0.25%
+150,000
New +$5.52M
OM icon
58
Outset Medical
OM
$86.4M
$5M 0.23%
+6,667
New +$5.48M
OBIO icon
59
Orchestra BioMed
OBIO
$228M
$4.4M 0.2%
+400,000
New +$4.49M
PANA.U
60
DELISTED
Panacea Acquisition Corp. Units, each consisting of one share of Class A common stock and one-third
PANA.U
$3.6M 0.17%
+300,000
New +$3.45M
TNGX icon
61
Tango Therapeutics
TNGX
$4.21B
$3.11M 0.14%
+300,000
New +$3.06M
CELL
62
DELISTED
PhenomeX Inc. Common Stock
CELL
$1.91M 0.09%
+25,000
New +$1.59M
NRIX icon
63
Nurix Therapeutics
NRIX
$2.45B
$1.75M 0.08%
+50,000
New +$1.26M
INZY
64
DELISTED
Inozyme Pharma
INZY
$1.63M 0.08%
+61,855
New +$1.54M
ACCD
65
DELISTED
Accolade Inc
ACCD
$1.55M 0.07%
+40,000
New +$1.38M
AMWL icon
66
American Well
AMWL
$180M
$1.48M 0.07%
+2,500
New +$1.32M
RLAY icon
67
Relay Therapeutics
RLAY
$4B
$1.28M 0.06%
+30,000
New +$1.14M
ANNX icon
68
Annexon
ANNX
$796M
$1.14M 0.05%
+37,570
New +$881K
ALEC icon
69
Alector
ALEC
$169M
– –
-686,400
Closed -$16.8M
ASND icon
70
Ascendis Pharma A/S
ASND
$16.5B
– –
-118,900
Closed -$17.6M
AVDL
71
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-457,951
Closed -$3.7M
AZN icon
72
AstraZeneca
AZN
$269B
– –
-162,995
Closed -$17.2M
CHRS icon
73
Coherus Oncology
CHRS
$217M
– –
-1,023,500
Closed -$18.3M
CRSP icon
74
CRISPR Therapeutics
CRSP
$4.69B
– –
-274,300
Closed -$20.2M
EDIT icon
75
Editas Medicine
EDIT
$399M
– –
-600,000
Closed -$17.7M
1 2
3
4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2020 Portfolio in Review

As of Q3 2020, Avidity Partners Management held 102 positions worth $2.16B, up 38% from $1.56B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Avidity Partners Management deployed $655M of net new capital in Q3 2020, opening 45 new positions and adding to 15 existing holdings. Its largest new stake was Merck: 1,199,226 shares worth $94.9M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 92% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Exelixis, an estimated $44.9M trimmed.

  • Avidity Partners Management's largest Q3 2020 buy was Merck: 1,199,226 shares worth $94.9M.
  • Avidity Partners Management added most to Avantor in Q3 2020, an estimated $61.3M increase.
  • Avidity Partners Management's biggest Q3 2020 reduction was Exelixis, cutting an estimated $44.9M.
  • Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q3 2020, selling an estimated $82.4M.
  • Avidity Partners Management's ten largest holdings make up 48% of its $2.16B portfolio in Q3 2020.
  • Avidity Partners Management opened 45 new positions and closed 34 in Q3 2020.
  • Avidity Partners Management's portfolio value rose 38% quarter-over-quarter to $2.16B.

Based on Avidity Partners Management's 13F filing for Q3 2020, filed 16 Nov 2020.